562-P: The Effect of Vitamin D Supplementation on the Cytokines Levels in Patients with Type 2 Diabetes Mellitus and Diabetic Neuropathy

Abstract

Background: Inflammation plays an important role in the pathogenesis of diabetic neuropathy (DN) in patients with type 2 diabetes (DM2). It seems that vitamin D ((VitD) could be involved in this process, however, the relationship between VitD status and inflammatory markers has not been wildly studied. Hypothesis: The aim was to study the association between VitD status and inflammatory markers in patients with DM2 and DN. Methods: The single-centre randomized study included 62 subjects with DM2 and DN (more than 4 points according to NDS), HbA1c up to 9%. Antihyperglycemic treatment was stable during the study. Patients were randomized in two groups: 5000 IU (group I) and 40000 IU (group II) of cholecalciferol supplementation per week. Body mass index (BMI), glycated hemoglobin (HbA1c), serum 25(OH)D level, Interleukins 6, 10 (IL-6, IL-10) were determined at baseline and after 24 weeks of treatment. The correlation analysis was evaluated by Pearson test. Results: Group I (n = 31, F16) and Group II (n = 31, F15) were matched for age, gender, BMI and baseline HbA1c levels. VitD insufficient/deficiency was revealed in 78% of diabetic patients with DN. After 6 months of VitD supplementation, the BMI, HbA1c and IL-6 levels significantly decreased, and 25(OH)D and IL-10 concentration increased only in Group II. We found associations between serum 25(OH)D and IL-6 (r = -0.912, p = 0.017) as well as IL-10 (r = 0.903, p = 0.014), and between HbA1c and IL-6 (r = 0.825, p = 0.031) and IL-10 (r = -0.897, p = 0.025) exclusively in Group II after treatment. Conclusions: VitD supplementation in 40000 IU of cholecalciferol per week during 6 months was associated with improved vitamin D status, pro-inflammatory markers and better glycemic control in patients with DM2 and DN. Vitamin D supplementation in 5000 IU per week did not change vitamin D status and inflammatory markers in this population. Disclosure A.P. Stepanova: None. T.L. Karonova: None. M. Galagoudza: None. E.Y. Vasileva: None. E.B. Jude: None.

Correlation between premorbid IL-6 levels and COVID-19 mortality: Potential role for Vitamin D

“…The final column details reported statistical effect of Vitamin D at lowering IL-6 level. Reference Location Condition Age (yrs] N Duration (wks] D3 Dose (IU/day) Outcome Bueloni-Dias [39] Brazil Healthy Women 57 ± 7 160 39 1000 p < 0.05 Costenbader [40] Boston Healthy Older Adults 65 ± 8 1561 52 2000 p > 0.05 Duggan [41] Seattle Overweight Women 62 ± 12 218 52 2000 p = 0.004 Goncalves-Mendes [42] France Healthy Older Adults 71 ± 6 38 13 6667 p = 0.046 Hashemi [43] Iran Multiple Sclerosis 30 ± 9 75 8 7143 p < 0.001 Hashemi [44] Iran Multiple Sclerosis 30 ± 10 75 8 7143 p < 0.001 Miroliaee [45] Iran Ventilator Pneumonia 56 ± 20 46 Single 300,000 p = 0.01 Reid [46] St Louis Asthma 40 ± 13 100 12 4000 p > 0.05 Stepanova [47] Russia Type 2 Diabetes Not Stated 62 …”

Effect of Vitamin D Supplementation on Inflammatory Markers in Non-Obese Lebanese Patients with Type 2 Diabetes: A Randomized Controlled Trial

“…Furthermore, previous studies disclosed that vitamin D might prevent the production of IL-6 [45][46][47] and thus could assist in reducing the incidence of type 2 diabetes mellitus [48]. Stepanova et al [49] concluded in their recent single-center randomized trial that the group receiving 40,000 IU cholecalciferol per week for a period of six months showed an improvement in serum IL-6 (p = 0.017). Unfortunately, within this analysis, vitamin D treatment did not support this hypothesis, since the changes observed in IL-6 concentrations were not significant in our T2DM subjects.…”